Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PK and safety study of oral edaravone suspension given orally vs via nasogastric tube in healthy adults
jRCT2031200361Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edaravone in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Pharmacokinetic assessments and Safety and tolerability. Started Feb 2021; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2031200361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200361.